公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2013 | Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients | Yuan Q.; Song L.-W.; CHUN-JEN LIU ; Li Z.; Liu P.-G.; Huang C.-H.; Yan Y.; Ge S.-X.; Wang Y.-B.; Peng C.-Y.; Zhang J.; JIA-HORNG KAO ; DING-SHINN CHEN ; PEI-JER CHEN ; Xia N.-S. | Gut | 67 | 63 | |
2015 | Rapid prediction of treatment futility of boceprevir with peginterferon-ribavirin for Taiwanese treatment experienced hepatitis C virus genotype 1-infected patients | Yang C.-C.; Tsai W.-L.; Su W.-W.; Huang C.-F.; Cheng P.-N.; Lo C.-C.; Tseng K.-C.; Mo L.-R.; Wang C.-H.; SHIH-JER HSU ; Lai H.-C.; Su C.-W.; CHUN-JEN LIU ; Peng C.-Y.; Yu M.-L. | PLoS ONE | 8 | 5 | |
2012 | Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients | Kao J.-T.; Lai H.-C.; Tsai S.-M.; Lin P.-C.; Chuang P.-H.; Yu C.-J.; Cheng K.-S.; Su W.-P.; PING-NING HSU ; Peng C.-Y.; Wu Y.-Y. | Liver International | 47 | 40 | |
2019 | Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study | CHEN-HUA LIU ; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 8 | 8 | |
2020 | Real-world effectiveness from the asia pacific rim liver consortium for hbv risk score for the prediction of hepatocellular carcinoma in chronic hepatitis b patients treated with oral antiviral therapy | Yang H.-I.; Yeh M.-L.; Wong G.L.; Peng C.-Y.; Chen C.-H.; Trinh H.N.; Cheung K.-S.; Xie Q.; TUNG-HUNG SU ; Kozuka R.; Lee D.-H.; Ogawa E.; Zhao C.; Ning H.-B.; Huang R.; Li J.; Zhang J.Q.; Ide T.; Xing H.; Iwane S.; Takahashi H.; Wong C.; Wong C.; Lin C.-H.; Hoang J.; Le A.; Henry L.; Toyoda H.; Ueno Y.; Gane E.J.; Eguchi Y.; Kurosaki M.; Wu C.; Liu C.; Shang J.; Furusyo N.; Enomoto M.; JIA-HORNG KAO ; Yuen M.-F.; Yu M.-L.; Nguyen M.H. | Journal of Infectious Diseases | 58 | 49 | |
2014 | Recovery of metal ions from spent Lithium Ion Batteries (LIBs) using sodium salts of D2EHPA or P507: Performance evaluation and life cycle assessment | Hung S.-H.; Lin C.-F. ; Chiang P.-C.; Tsai T.-H.; Peng C.-Y. | Research Journal of Chemistry and Environment | 1 | ||
2021 | Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy | Lin H.-H.; SHIH-JER HSU ; Lu S.-N.; Chuang W.-L.; Hsu C.-W.; Chien R.-N.; Yang S.-S.; Su W.-W.; Wu J.-C.; Lee T.-H.; Peng C.-Y.; Tseng K.-C.; Qin A.; Huang Y.-W.; PEI-JER CHEN | JGH Open | 12 | 12 | |
2018 | SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma | Chow P.K.H.; Gandhi M.; Tan S.-B.; Khin M.W.; Khasbazar A.; Ong J.; Choo S.P.; Cheow P.C.; Chotipanich C.; Lim K.; Lesmana L.A.; Manuaba T.W.; Yoong B.K.; Raj A.; Law C.S.; Cua I.H.Y.; Lobo R.R.; Teh C.S.C.; Kim Y.H.; Jong Y.W.; Han H.-S.; Bae S.-H.; Yoon H.-K.; Lee R.-C.; Hung C.-F.; Peng C.-Y.; PO-CHIN LIANG ; Bartlett A.; Kok K.Y.Y.; Thng C.-H.; Low A.S.-C.; Goh A.S.W.; Tay K.H.; Lo R.H.G.; Goh B.K.P.; Ng D.C.E.; Lekurwale G.; Liew W.M.; Gebski V.; Mak K.S.W.; Soo K.C. | Journal of Clinical Oncology | 445 | 394 | |
2022 | Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan | Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; CHUN-JEN LIU ; Dai C.-Y.; Lin H.-C.; JIA-HORNG KAO ; Chuang W.-L.; Yu M.-L.; TACR investigators | Infectious Diseases and Therapy | 9 | 8 | |
2021 | Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan | CHEN-HUA LIU ; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; CHUN-JEN LIU ; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; YU-JEN FANG ; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; CHIEN-CHING HUNG ; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T. Y.; JIA-HORNG KAO | Hepatology International | 14 | 14 | |
2021 | Sofosbuvir/velpatasvir plus ribavirin for child-pugh b and child-pugh c hepatitis c virus-related cirrhosis | CHEN-HUA LIU ; Chen C.-Y.; Su W.-W.; CHUN-JEN LIU ; Lo C.-C.; Huang K.-J.; Chen J.-J.; Tseng K.-C.; Chang C.-Y.; Peng C.-Y.; Shih Y.-L.; Huang C.-S.; Kao W.-Y.; Yang S.-S.; Tsai M.-C.; Wu J.-H.; Chen P.-Y.; Su P.-Y.; Hwang J.-J.; YU-JEN FANG ; Lee P.-L.; Tseng C.-W.; Lee F.-J.; Lai H.-C.; Hsieh T.-Y.; Chang C.-C.; Chang C.-H.; Huang Y.-J.; JIA-HORNG KAO | Clinical and Molecular Hepatology | 8 | 8 | |
2020 | Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment | CHEN-HUA LIU ; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; CHUN-JEN LIU ; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; YU-JEN FANG ; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; JIA-HORNG KAO | Gut | 26 | 27 | |
2017 | Spectroelectrochemical and adhesion properties of chemically synthesized ion conducting poly (vinyl butyral) in Prussian blue and poly (3, 4-ethylenedioxythiophene) laminated electrochromic glazing | Huang L.-M.; Peng C.-Y.; Hu C.-W.; Lu H.-C.; Chen C.-H.; Yang D.-J.; Kuo C.-C.; Ho K.-C. | Solar Energy Materials and Solar Cells | 12 | 10 | |
2020 | Successful antiviral therapy reduces risk of schizophrenia among chronic hepatitis c patients: A nationwide real-world Taiwanese cohort (T-COACH) | Tsai P.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Hsieh M.-H.; Huang J.-F.; Dai C.-Y.; Chung W.-L.; Ke C.-L.K.; Yu M.-L.; T-COACH Study Group | Open Forum Infectious Diseases | 3 | 3 | |
2020 | Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis | Hsu W.-F.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Tsai P.-C.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. | Scientific Reports | 4 | 4 | |
2019 | Taiwan consensus statement on the management of chronic hepatitis B | Chien R.-N.; JIA-HORNG KAO ; Peng C.-Y.; Chen C.-H.; CHUN-JEN LIU ; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; YEN-HSUAN NI ; Chuang W.-L.; Lee C.-M.; Wu J.-C.; PEI-JER CHEN ; Liaw Y.-F. | Journal of the Formosan Medical Association | 50 | 47 | |
2021 | Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients | Liu M.; TAI-CHUNG TSENG ; Jun D.W.; Yeh M.-L.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung M.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO ; Yang H.-I.; Nguyen M.H. | Hepatology International | 14 | 14 | |
2018 | Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study | JIA-HORNG KAO ; Yu M.-L.; Chen C.-Y.; Peng C.-Y.; Chen M.-Y.; Tang H.; Chen Q.; Wu J.J. | Journal of Gastroenterology and Hepatology (Australia) | 15 | 11 | |
2013 | Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir | Wang C.-C.; Tseng K.-C.; Peng C.-Y.; Hsieh T.-Y.; Lin C.-L.; TUNG-HUNG SU ; TAI-CHUNG TSENG ; Hsu C.-S.; Lin H.H.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 24 | 26 | |
2005 | YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models | Pan S.-L.; JIH-HWA GUH ; Peng C.-Y.; Wang S.-W.; Chang Y.-L.; Cheng F.-C.; Chang J.-H.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Journal of Pharmacology and Experimental Therapeutics | 55 | 53 |